Metagenomi Therapeutics, Inc. Capital Expenditures
Metagenomi Therapeutics, Inc. (MGX) reported Capital Expenditures of $150.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $125.00K, a 1.57% decline year-over-year.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $25.00K, a 91.32% decline year-over-year.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $85.00K, a 74.55% decline year-over-year.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $74.00K, a 93.83% decline year-over-year.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $574.00K, a 81.57% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $3.11M, a 68.27% decline from fiscal 2023.
- Metagenomi Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $9.81M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $150.00K 10-Q · filed 2026-08-10 | $235.00K derived: sum of 3 quarters · filed 2026-08-10 | $309.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-11 | $110.00K derived: sum of 2 quarters · filed 2026-05-11 | $184.00K derived: sum of 3 quarters · filed 2026-05-11 | $311.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $159.00K derived: sum of 2 quarters · filed 2026-03-05 | $286.00K derived: sum of 3 quarters · filed 2026-08-10 | $574.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $201.00K derived: sum of 2 quarters · filed 2026-08-10 | $489.00K 10-Q · filed 2025-11-12 | $823.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $415.00K 10-Q · filed 2026-08-10 | $749.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $288.00K 10-Q · filed 2026-05-11 | $622.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.82M derived: sum of 3 quarters · filed 2026-05-11 | $2.49M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.53M derived: sum of 2 quarters · filed 2026-03-05 | $2.20M derived: sum of 3 quarters · filed 2026-03-05 | $3.11M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.86M derived: sum of 2 quarters · filed 2025-11-12 | $2.78M 10-Q · filed 2025-11-12 | $4.52M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $665.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.58M 10-Q · filed 2025-08-12 | $3.32M derived: sum of 3 quarters · filed 2025-08-12 | $5.58M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $915.00K 10-Q · filed 2025-05-13 | $2.65M derived: sum of 2 quarters · filed 2025-05-13 | $4.91M derived: sum of 3 quarters · filed 2025-05-13 | $8.06M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.00M derived: sum of 2 quarters · filed 2025-03-17 | $7.15M derived: sum of 3 quarters · filed 2025-03-17 | $9.81M 10-K · filed 2025-03-17 |
| 2023-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $5.41M derived: sum of 2 quarters · filed 2024-11-13 | $8.08M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.82M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $2.67M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |